Advagene Biopharma Co., Ltd. engages in the development of products such as nasal influenza vaccine, airway allergy immunotherapy and COVID-19 immunotherapy. The company was founded on September 19, 2006 and is headquartered in Taipei, Taiwan.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company